Vol. XXX, n.3, 2009 ISSN: 0392-2936


european journal
of gynaecological oncology

an International Journal


Founding Editor
A. Onnis
Montréal (Canada)

Editors-in-Chief
M. Marchetti
Montréal (Canada)
P. Bösze
Budapest (Hungary)

Associate Editor
T. Maggino
Padua (Italy)

Assistant Editor
J. Wilson
San Diego - CA (USA)
Editorial Board
Allen H.H., London, Ontario (Canada)
Anteby S.O., Jerusalem (Israel)
Audet-Lapointe P., Montreal (Canada)
Ayhan A., Ankara (Turkey)
Balat O., Graziantep (Turkey)
Ba˘nceanu G., Bucarest (Romania)
Basta A., Krakow (Poland)
Bender H.C., Dusseldorf (Germany)
Benedetti Panici P.L., Rome (Italy)
Charkviani T., Tbilisi (Georgia)
De Oliveira C.F., Coimbra (Portugal)
Dexeus S. Jr., Barcelona (Spain)
Di Paola G.R.,
Buenos Aires (Argentina)
Di Re F., Milan (Italy)
Di Saia P., Orange, CA (USA)
Friedrich M., Hamburg (Germany)
Fuller A.F. Jr., Boston, MA (USA)
Geisler H.E., Indianapolis, IN (USA)
Gerbaulet A., Villejuif (France)
Gorins A., Paris (France)
Heintz A.P.M.,
Utrecht (The Netherlands)
Ioannidou-Mouzaka L.,
Athens (Greece)
Jordan J.A.,
Birmingham, England (UK)
Karseladze A.I., Moscow (Russia)
Klastersky J., Bruxelles (Belgium)
Kubista E., Vienna (Austria)
Maggino T., Padua (Italy)
Markowska J., Poznan (Poland)
Marth C., Innsbruck (Austria)
Massuger Leon F.A.G.,
Nijmegen (The Netherlands)
Menczer J., Savyon (Israel)
Monsonego J., Paris (France)
Pálfalvi L., Budapest, (Hungary)
Pinotti A., São Paulo (Brazil)
Piura B., Beer Sheva (Israel)
Piver S.M., Buffalo, NY (USA)
Rakar S., Ljubljana (Slovenia)
Raju K.S., London, England (UK)
Shepherd J.H.,
London, England (UK)
Stelmachów J., Warsaw (Poland)
Tjalma W., Antwerpen (Belgium)
Ungár L., Budapest (Hungary)
Vermorken J.B., Edegem (Belgium)
Wang P.-H., Taipei (Taiwan)
Winter R., Graz (Austria)
Yokoyama Y., Hirosaki (Japan)

Publishing Organization (M. Morsani):
I.R.O.G. CANADA, Inc. - 4900 Côte St-Luc - Apt # 212 - Montréal, Qué. H3W 2H3 (Canada)
Tel. +514-4893242 - Fax +514-4854513 - E-mail: canlux@mgroup-online.com - www.irog.net

Editorial Office (M. Critelli):
Galleria Storione, 2/A - 35123 Padua (Italy) - Tel. (39) 049 8756900 - Fax (39) 049 8752018

 

EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed works in the fields of female genital cancers and related subjects and also proceedings of gynecologic oncology society meetings all over the world. The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE, EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

 

European Journal of Gynaecological Oncology
www.irog.net


General Information

The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY (ISSN 0392-2936) publishes original peer reviewed work, preferably brief reports, in the fields of female genital cancers and related subjects – prevention, early detection, epidemiology, pathology, diagnosis, management – and also proceedings of Gynaecologic Oncology Society meetings all over the world.

The Journal is covered by CURRENT CONTENTS, SCISEARCH, RESEARCH ALERT, INDEX MEDICUS, MEDLINE,
EMBASE/ Excerpta Medica, CURRENT ADVANCES IN CANCER RESEARCH, BIOSIS.

AIMS AND SCOPE
The EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY is dedicated to publishing editorial articles in the “Distin-guished Expert Series” and original research papers, case reports, letters to the Editor, book reviews and newsletters.

The Journal was founded in 1980 – the second gynaecologic oncology hyperspecialization journal in the world. Its aim is the dif-fusion of scientific, clinical and practical progress and knowledge in female neoplastic diseases in an interdisciplinary approach among gynaecologists, oncologists, radiotherapists, surgeons, chemotherapists, pathologists, epidemiologists and so on.

ANNOUNCEMENTS regarding meetings, postgraduate courses and symposia will be accepted 6 months before publication and will be published free of charge.
BOOK SAMPLES for review should be sent to the Editorial offices in Montréal or in Padova.
COPYRIGHT: the Journal has been registered with the Copyright Clearance Center, Inc. Reproductions are not allowed without the written consent of the Publisher. All photocopy fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA stating the ISSN number, the volume and the first and last page numbers of each article copied.
ADVERTISING INFORMATION: advertising orders and inquiries may be sent to: I.R.O.G. CANADA Inc., Publisher, 4900 Côte St. Luc, Apt. 212, Montréal (Quebec) Canada H3W 2HS, Tél. 514.4893242-4893640 - Fax 514.4854513 - E-mail: canlux@mgroup-online.com - www.irog.net
RESPONSIBILITY: although every effort is made by the editorial staff and the printer to eliminate misleading or inaccurate infor-mation, the publisher accepts no responsibility for the consequences of faultful or incorrect information. The authors recognize that the editor and publisher have no responsibility and are indemnified against any liability or claim that may result from the publication of misleading or incorrect data.


SUBSCRIPTION INFORMATION
The Journal is published bimonthly (January, March, May, July, September and November); one volume per year. Subscriptions start from January and are automatically renewed if not cancelled by the end of September.

Subscriptions include six issues per year plus supplements, monographs and all official communications of Meetings, Courses, Symposia and all scientific activities of Gynaecologic Oncology Societies all over the world.

Subscriptions are entered with prepayment only. The annual subscription is $390 US for Institutions, $200 US for Individuals. For airmail add $30, for receipt add $10 US. Single copy prepaid cost $95 US.

Send subscription requests with cheque or credit card payment (Amex - Visa - Diner’s - Master Card) to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, Montréal, Québec H3W 2H3 Canada. Only US Funds are accepted. No bank transfers.

Claims for missing issues can be honoured up to six months. Changes of address: allow six weeks for all changes to become effec-tive. All communications should include both old and new addresses (with postal codes) – better if accompanied by a mailing label from a recent issue – and should be sent to the printer: La Garangola, Via E. Dalla Costa 6, 35129 Padova (Italy) or by Fax +39.049.7806580. Claims should be made within six months of publication date.

Duplicate copies will not be sent to replace those undelivered through failure to notify of change of address.

Single copies and back issue and volume information is available from the printer, La Garangola, Padova, Tel. +39.049.8075557, Fax +39.049.7806580. Certain back issues may only be available as photocopies of the originals.

All other business correspondence including orders for offprints and advertising space and any communication and requests should be addressed to I.R.O.G. CANADA Inc., 4900 Côte St. Luc, Apt. 212, MONTRÉAL, QUÉBEC H3W 2H3 (Canada), tel. (514) 4893242, fax (514) 4854513.

IN ALL LEGAL MATTERS THE COURT OF MONTREAL IS COMPETENT

 

European Journal of Gynaecological Oncology
www.irog.net


Instructions to Authors

SUBMISSION OF MANUSCRIPTS
Papers should be submitted to A. ONNIS Editor-in-Chief of the EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 4900 Côte St. Luc, Apt. 212 MONTREAL, QUÉBEC H3W 2H3 (Canada) - Tel. +514-4893242 - Fax +514-4854513, or Galleria Sto-rione 2/A - 35123 PADOVA (Italy) - Fax +39-049-8752018.

Editorial articles for publication in the “Distinguished Expert Series” should be submitted to P. Bösze, Editor-in-Chief of this section, Department of Gynecology, Saint Stephan Hospital, 1096 Budapest, Nagyvárad tér 1, Telephone (36-1) 275 2172, Fax (36-1)
275 2172, E-mail: bosze@axelero.hu

When a manuscript is submitted, an acknowledgement card is sent to the corresponding author within two or three weeks.

Submitted papers are reviewed by the Editor-in-Chief and his Peer Referees. Authors may be required to modify the manuscript according to the reviewers’ suggestions.

Manuscripts accepted for publication will be copyedited by the editorial staff for typographical and grammatical mistakes and to guarantee clarity and conciseness.

Publication time will be the shortest possible based on scientific and publishing needs. Manuscripts submitted for publi-cation cannot be returned.

Published papers will become property of the Journal and copyrighted under I.R.O.G. CANADA Inc.

After six months no grievances will be accepted regarding published articles.

All statements are the responsibility of the authors. Product dosages, indications and methods referred to in the papers reflect the author’s experience. No responsibility is assumed by the Editor-in-Chief or the Publisher for any damage from use of any products, operation methods or instructions contained in the published materials.

Trade names, trademarks, etc. are protected by the law and regulations. The Editor-in-Chief and the Publisher cannot accept any legal responsibility for any errors or omissions that may be made in press, particularly for information about drug dosage and appli-cation thereof contained in the Journal. Consult the prescribing information before administering any drug.

MANUSCRIPT REQUIREMENTS
The Journal follows the “Uniform requirements for manuscripts submitted to biomedical journals” published in the New England Journal of Medicine 1991, 324, 424-8 and in the British Medical Journal 1991, 302.

Three manuscripts, typed and double spaced should be submitted with an electronic disk, formatted in Word for Macintosh or Windows, version 6.0. Manuscripts without an electronic disk will not be accepted. A cover letter signed by all authors must state that all authors who have participated in the work take responsibility for the manuscript which has never been pub lished or submitted for publication elsewhere. Without a cover letter the publication will not be possible. Name, address and phone/fax numbers of the Corresponding Author, responsible for revision and approval of the proofs, should be indicated. Full-length articles should not exceed 8 printed pages including tables and references.

After the title page (full title and names of authors, institutions, eventual acknowledgement for financial support, running title of no more than 60 characters or spaces), original works should be arranged in the conventional order: Summary (purpose of investiga-tion, methods, results, conclusion - about 150 words), Key words, Content (a 20-word summary), Introduction, Materials and Methods, Results, Discussion, Conclusion, Acknowledgement (if any), References, Tables, Legends.

Authors should supply a complete address for reprint requests.

In the text only standard abbreviations can be used and must be avoided in the title. The full term for which an abbreviation stands should precede its first use in the summary and text unless it is a standard unit of measurement.

Authors must give their complete professional identifications and affiliations, including all academic titles and positions.

Letters to the editor should be brief (500 words or less) and offer objective, constructive and educational criticism of published material. The editor reserves the right to publish.

Figures: Two original copies (not negatives) of each figure are requested. Each figure should have a label on the back indicating its number, author’s name and top of the figure. Do not write on the back of the figures and do not mount them on cardboard. If sending colour pictures advise if they must be printed in colour or black and white (colour costs ten times more).

Legends should be typed on a separate page with Arabic numerals corresponding to the illustrations.

Tables should be titled, typed in double space on separate pages and numbered in Arabic numerals in the order of their first cita-tion
in the text. Do not use internal rules. Only standard, universally understood abbreviations should be used.

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in the text, tables, and legends by Arabic numerals in parentheses.

Use the style of the examples below, which are based with slight modifications on the format used by the U.S. National Library of Medicine in Index Medicus. The titles of journals should be abbreviated according to the style used in Index Medicus.

References must be verified by the Author(s) against the original documents.

Examples of correct forms of references are given below:

Articles in Journals: Authors’ surname and initials (if more than six names, give six followed by “et al.”), Title, Abbreviated Journal Title, Year of Publication, Volume, Issue and first page.

Books: Authors’ surname and initials, title of the book and title of chapter, in: Title, Editor(s), Place, Publisher, Year, Page.

Acknowledgments
will be limited to appropriate professionals who were contributors to the paper.

PROOFS revised by the editorial staff will be sent to the corresponding author and should be checked and returned within ten days. The corresponding author is responsible for detecting typesetting errors. After this deadline the proofs will be considered approved. Only essential corrections should be made; extensive changes will be charged to the authors.

BUSINESS MATTERS
The Journal has no commercial advertisements.

Authors will be expected to contribute to the printing expenses, tables, figures and postage. For every published article a copy of the Journal will be provided free of charge. Only payments in US dollars will be accepted. No bank transfers.

Reprints should be requested with the form enclosed with the acceptance letter. No free reprints will be supplied.



© By I.R.O.G. CANADA INC. - Publisher - Editorial office 4900 Côte St. Luc - Apt. 212 - Montréal Québec H3W 2H3 (Canada) - Tel. (514) 4893242-4893640 - Fax (514) 4854513 - Printed in Italy by “La Garangola” - Via E. Dalla Costa, 6 - 35129 Padua (Italy) - Responsible Director: Prof. Antonio Onnis M.D. - Authorization of Padua’s Court n. 633 - 28-6-1979
   
European Journal of Gynaecological Oncology - Vol. XXX, n.3, 2009
 
   
CONTENTS  
REVIEW ARTICLE  
Is there a role for neoadjuvant chemotherapy in early invasive cervical carcinoma? 249
G. Cormio, V. Loizzi, C. Carriero, G. Putignano, L. Selvaggi - Bari, ITALY
The purpose of this study was to determine if a survival advantage may exist from neoadjuvant chemotherapy (NACT) followed by radical surgery in early invasive (Stage IB1 and IIA) cervical carcinoma.
 
 
ORIGINAL ARTICLES  
Patterns of surgical care for uterine cancers in Ontario 255
L. Elit, S. Schultz, R. Prysbysz, J. Kwon, R. Saskin, N. Gunraj, A.S. Wilton, M. Simunovic, D. Urbach - Toronto, CANADA
An evaluation of operative services provided for uterine cancer in Ontario.
 
Glucocorticoid receptor expression in cervical intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix 259
F. Buxant, D. Bucella, V. Anaf, P. Simon, J.C. Noël - Brussels, BELGIUM
Demonstration of the persistence of glucocorticoid receptor in cervix cancer.
 
Histone deacetylase inhibitor trichostatin A modulates cell cycles in A2780 human ovarian cancer cell lines 263
X.X. Ma,Y.N. Jin, Q. Miao, S. Li,Y.Q. He, H.W. Lv - Shenyang, CHINA
The effect of trichostatin A on modulating cell cycles in A2780 human ovarian cancer cell lines was studied.
 
Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions 267
M. Guida, F. Sanguedolce, P. Bufo, A. Di Spiezio Sardo, G. Bifulco, C. Nappi, G. Pannone - Naples, ITALY
Simultaneous hypermethylation of hMLH1 and CDKN2A/p16 promoters may represent an early event in endometrial carcinogenesis.
 
Role of HPV DNA testing for detection of high-grade cervical lesions in women with atypical squamous cells of undetermined significance: A prospective study in a Korean population 271
J.H. Yoon, S.C. Yoo,W.Y. Kim, S.J. Chang, K.H. Chang, H.S. Ryu - Suwon, KOREA
HPV testing is useful for predicting high-grade cervical lesions in women with ASC-US and formulating decisions with regard to treatment plans.
 
Antiproliferative effects of 2-methoxyestradiol alone and in combination with chemotherapeutic agents on human endometrial cancer cells 275
C.H. Chen,W.J. Lee, T.C. Chang, R.J. Chen, C.H. Chien, S.N. Chow - Taipei, TAIWAN
In vitro synergistic effects of 2-methoxyestradiol and paclitaxel support the basis of the clinical application of combination chemotherapy to patients with endometrial cancer.
 
Elevated blood active ghrelin and normal total ghrelin and obestatin concentrations in uterine leiomyoma 281

A. Markowska, A. Ziolkowska, K. Nowinka, L.K. Malendowicz - Poznan, POLAND
The role of active ghrelin in the development of uterine myoma is studied.

 
Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer 285
B.B. da Silva, P.V. Lopes-Costa, A.R. dos Santos, E.C. de Sousa-Júnior, A.P. Alencar, C.G. Pires, M.A. Rosal - São Paulo, BRAZIL
Microvessel density assessed by anti-CD34 was significantly greater than that evaluated by anti-CD31 or anti-factor VIII-related antigen.
 
Ovarian cancer: lymph node metastases 289
G. Balbi, M.A. Manganaro, A. Monteverde, I. Landino, C. Franzese, F. Gioia - Naples, ITALY
Bilateral pelvic and paraaortic lymphadenectomy is necessary in ovarian cancer because there is a high prevalence of both pelvic and paraaortic lymph node metastases.
 
ERBB2 (HER2) protein expression in uterine sarcomas 292
M. Zafrakas, L. Zepiridis, T.D. Theodoridis, I.D. Venizelos, A. Papanicolaou, T. Agorastos, J.N. Bontis - Thessaloniki, GREECE
ERBB2 (HER2) expression was analyzed immunohistochemically in primary uterine sarcomas and was found to be very weak in the majority of tumors.
 
Empirical accuracy of fine needle aspiration cytology (FNAC) for preoperative diagnoses of malignant breast lumps in hospitals with restricted health resources 295
J. Patumanond, T. Kayee, U. Sukkasem - Chiang Mai, THAILAND
Preoperatively fine needle aspiration cytology together with patient age and size of breast lump correctly predicted 95% of breast malignancy.
 
Incidence of port-site metastasis after laparoscopic management of borderline ovarian tumors: a series of 22 patients 300
R. Berretta, M. Rolla, T.S. Patrelli, D. Gramellini, G.M. Fadda, G.B. Nardelli - Parma, ITALY
Incidence of port-site metastasis after laparoscopic management of borderline ovarian tumors: a series of 22 patients.
 
The role of telomerase activity in predicting early recurrence of epithelial ovarian cancer after first-line chemotherapy: a prospective clinical study 303
B. Özmen, C.I. Duvan, G. Gümüs ¸, M. Sönmezer, M. Gungor, F. Ortac ¸ - Ankara, TURKEY
Telomerase activity has no significant role in detection of early recurrence in epithelial ovarian cancer.
 
Radical abdominal trachelectomy in managing early cervical invasion 309
K. Jeremic, S. Petkovic, A. Stefanovic, J. Stojnic, M. Maksimovic, I. Likic, J. Atanackovic - Belgrade, SERBIA
An effort to preserve fertility in young women affected by early-stage cervical cancer was performed via abdominal radical trachelectomy with lymphadenectomy.
 
 
CASE REPORTS  
Ineffective attempt to preserve fertility with a levonorgestrel-releasing intrauterine device in a young woman with endometrioid endometrial carcinoma: a case report and review of the literature 313
I. Vandenput, K. Van Eygen, Ph. Moerman, I. Vergote, F. Amant - Leuven, BELGIUM
A case of a young, nulliparous woman with endometrioid endometrial cancer unsuccessfully treated with a levonorgestrel intrauterine contraceptive device.
 
Adenoid cystic carcinoma of Bartholin’s gland with lung metastasis: a case report 317
X. Wang,W. Lu, C. Zhu, F. Ye, X. Xie - Hangzhou,CHINA
Initial conservative surgery on a local lesion and later stage of adenoid cystic carcinoma of the Bartholin’s gland could be considered.
 
Small cell neuroendocrine carcinoma of the cervix: report of two cases 321
F. Puig, C. Rodrigo, G. Muñoz, R. Lanzón - Zaragoza, SPAIN
Small-cell neuroendocrine carcinoma of the uterine cervix is an uncommon neoplasm with an aggressive behavior.
 
Repeat chemosensitivity of epithelial ovarian carcinoma in a BRCA1 mutation carrier to paclitaxel/platinum combination chemotherapy 323
B. Melichar, P. Fridrichová, M. Tomsová, E. Malírová - Olomouc, CZECH REPUBLIC
Repeat chemosensitivity to the combination of paclitaxel/platinum is described in an epithelial ovarian carcinoma patient carrying the BRCA1 mutation.
 
Bone metastasis from endometrioid ovarian carcinoma: a case study and literature review 326
N. Baize, A. Mahamat, E. Benizri, M.C. Saint-Paul, N. Mounier - Nice, FRANCE
A case study and literature review of unique bone metastasis from endometrioid ovarian carcinoma is presented.
 
Limbic encephalitis associated with immature teratoma 329
H. de Lins e Horta, A. Fonseca de Castro, R. Porto Fonseca, A. Soares Fernandes Jr., V. Soares Lima, L. Carvalho Neuenschwander - Belo Horizonte, BRAZIL
A case of severe paraneoplastic limbic encephalitis associated with immature teratoma is reported together with a brief review of the literature.
 
Leiomyosarcoma of the broad ligament: a case report and review of the literature 332
A. Kolusari, G. Ugurluer, M. Kosem, M. Kurdoglu, R. Yildzhan, E. Adali - Van, TURKEY
A case of a 35-year-old pregnant patient affected by leiomyosarcoma of the broad ligament is described.
 
Fallopian tube carcinoma metastatic to the pericardium and breast 335
S. Buyukkurt, M.A. Vardar, H. Zeren, B. Guzel, I. Tuncer - Adana, TURKEY
A 46-year-old woman with tubal adenocarcinoma relapsed 41 months later with pericardial and breast metastasis.
 
Virilizing ovarian hilus (Leydig) cell tumor with concurrent contralateral hilus cell hyperplasia: a rare diagnosis 338
M. Zafrakas, I.D. Venizelos, T.D. Theodoridis, L. Zepiridis, T. Agorastos, J.N. Bontis - Thessaloniki, GREECE
An extremely rare case of virilizing ovarian hilus (Leydig) cell tumor with contralateral hilus cell hyperplasia is presented.
 
Hepatoid carcinoma of the ovary. A case report and review of the literature 341
A. Zizi-Sermpetzoglou, N. Petrakopoulou, M.E. Nikolaidou, N. Tepelenis, V. Savvaidou, Th. Vasilakaki - Piraeus, GREECE
Preoperatively fine needle aspiration cytology together with patient age and size of breast lump correctly predicted 95% of breast malignancies.
 
Giant uterine leiomyomas causing bilateral hydronephrosis coexisting with endometrial cancer in polyp: a case study 344
A. Semczuk, P. Skorupski, P. Olcha, D. Skomra, T. Rechberger, M. Gogacz - Lublin, POLAND
A case of giant uterine leiomyomas causing bilateral hydronephrosis coexisting with endometrioid-type endometrial cancer deriving from a polyp is presented.
 
Renal cell carcinoma in pregnancy: a case report 347
J. Stojnic, K. Jeremic, S. Petkovic, G. Lazovic, A. Stefanovic - Belgrade, SERBIA AND MONTENEGRO
A case of renal cell carcinoma diagnosed during pregnancy is described.